The EORTC trials for limited stage Hodgkin's disease

SINCE 1964, all the efforts of the Lymphoma Group of the EORTC (European Organisation for Research and Treatment of Cancer) have been devoted to the task of tailoring treatment to the presentation of Hodgkin’s disease (HD) for any given patient [l-12]. We will first briefly review the results of the four controlled studies conducted by the group from 1964 to 1988 for stages I and II HD. We will then present in detail the designs of the on-going H7 randomised trials for these same subsets of Hodgkin’s disease patients.